Your SlideShare is downloading. ×
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply



Published on



  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 2. (S)-alfa-ethyl-2-oxo-l-pyrrolidine- acetamide is a pyrrolidine derivative
  • 3. Chemical properties • Levetiracetam is a white powder ,wholly soluble in water. • racemically pure S-enantiomer . • The R-enantiomer devoid of anticonvulsant properties in animals
  • 4. Preclinical data • levetiracetam is not active against acute seizures, namely the maximal electroshock (MES) and pentylenetetrazol (PTZ) seizure tests • Levetiracetam also appears to lack anticonvulsant activity in other acute seizure tests utilizing chemoconvulsant agents,
  • 5. • levetiracetam does possess activity chronic epilepsy, such as kindled and genetic animals • reduces seizure severity, duration of motor seizures as well as after discharge duration in fully amygdala-kindled rats • effective in genetic animal models of epilepsy, such as the genetic absence epilepsy rat from Strasbourg (GAERS) (resembling human spike-wave conditions)
  • 6. • Wide safety margin between the effective dose (ED50; dose protecting 50% of animals from seizures) and the dose impairing rotarod performance(TD50; dose causing 50% of animals to lose equilibrium on the rotarod).
  • 7. mechanism of action • inhibits a specific high-voltage activated calcium channel, the N-type • inhibit the release of calcium from intracellular stores . • oppose the inhibitory action of zinc and beta- carbolines on GABAA- and glycine-gated currents • inhibits burst firing without affecting normal neuronal excitability • inhibit hypersynchronization of epileptiform activity, which distinguishes levetiracetam from other AEDs • stereoselective, saturable and reversible binding site specific for levetiracetam in the CNS,SV2A
  • 8. Pharmacokinetics • water-soluble compound, which is rapidly and almost completely absorbed after oral administration • Administration with food does not reduce the extent, but may slow the rate of absorption . • Bioavailability approaches 100% . • Peak plasma concentrations are reached in 1-2 h. • The pharmacokinetics are linear, • Levetiracetam is <10% protein bound.
  • 9. • Sixty-six per cent of the dose is excreted unchanged in the urine. • Twentyseven per cent of the dose is metabolized by an enzymatic hydrolysis of the acetamide group, mainly to L057 • This process occurs diffusely in the body, and is not hepatically mediated. • no inhibition of drug-metabolizing enzymes including CYP3A4, CYP1A2, CYP2C19, CYP2C9, CYP2E1, CYP 2D6, epoxide hydrolase and various uridine glucuronyltransferases
  • 10. • The metabolites of levetiracetam are renally excreted. • Because there is no hepatic metabolism, • and because levetiracetam does not induce or inhibit hepatic enzymes, • it does not interfere with the metabolism of other AEDs, • nor do other AEDs interact with its metabolism or elimination. • Probenecid increases plasma levels of the levetiracetam metabolite L057 2.5-fold, by a reduction in renal clearance
  • 11. children • The half-life of levetiracetam in children, as for most drugs, is shorter than adults. • After a single oral dose of 20mg/kg, values for Cmax and AUC equated for a 1-mg/kg dose were -30-40% lower than adults, whereas renal clearance was higher. • The half-life was ~6h
  • 12. elders Elderly individuals may have altered drug metabolism, • gastric mucosal atrophy • decreased gastric motility leading to altered absorption, • change in hepatic and renal function, • altered albumin levels. • Studies demonstrated a prolonged half-life, which could be explained entirely by reduced creatinine clearance • The elimination half-life is approximately 10-llh, compared to 7.7h in younger normal subjects • Adjustments in dosage should be made based on estimated creatinine clearance, taking body mass into account.
  • 13. Liver failure • Mild to moderate (Child-Pugh class A or B) hepatic impairment do not alter the clearance of levetiracetam, and no dosage adjustments are required. • However, in severe hepatic failure (Child-Pugh class C) there is a reduced clearance, most likely due to concomitant renal insufficiency . • Adjustments in dose should therefore be made based on renal rather than hepatic function.
  • 14. Renal failure patients with renal failure on dialysis, a dose of 500-1000 mg once daily is recommended, with a supplemental dose of 250-500 mg after dialysis treatment
  • 15. 31 -Betts T, Waegemans T, Crawford 32 Cereghino JJ etal. 33 . Shorvon SD etal 41 -Ben-Menachem E, Falter U .
  • 16. • The efficacy of levetiracetam in treatment of primary generalized epilepsy including tonic-clonic, absence and myoclonic epilepsy was reported in a recent small case series. • effective in juvenile myoclonic epilepsy (JME). Among 30 patients with resistant JME who received levetiracetam, 62% became seizure free • reports suggest that levetiracetam is potentially efficacious in photosensitive epilepsy • patients with progressive myoclonic epilepsy have experienced dramatic improvements with the addition of levetiracetam to their regimen • useful in the treatment of other epilepsies including atypical absence and atonic seizures
  • 17. indications Adjunctive to • Partial onset seizures in adults,children >4 yrs • Myoclonus in adults,children>12 yrs ,JME • Primary GTCS in adults,children>6 yrs
  • 18. Side-effects • Somnolence ,20.4% of patients on lOOOmg of levetiracetam vs. 18.8% on 3000 mg, as compared to 13.7% of placebo patients • asthenia. 14.7% vs. 9.1 % of placebo • nausea, • dizziness and headache. • Infections including upper respiratory tract (rhinitis and pharyngitis) and urinary tract infections • agitation, hostility, anxiety, apathy, emotional lability, depersonalization and depression,13.3% of levetiracetam patients compared to 6.2% in placebo • suicidal behaviour was reported in 0.5% vs. none for placebo group • In a pooled analysis, >25% worsening of seizures occurred during add-on trials in the placebo group (26%) than in the levetiracetam-treated group (14%) • Anemia,leukopenia
  • 19. • Idiosyncratic adverse effects • Teratogenicity • Adverse effects of levetiracetam in paediatric patients • Overdosage • Tolerance
  • 20. 50- Bourgeois B etal. 57- Wannag E, Eriksson A, Brockmeier, 59- Faircloth VC . etal 60- Strunc M, Levisohn P .
  • 21. Clinical therapeutics • highly water soluble, • Levetiracetam is not metabolized by the liver. • It is free of non-linear metabolic kinetics, autoinduction and drug-drug interactions • it lacks protein binding (<10%), which avoids the problem of displacement of highly protein-bound drugs. • potentially broadspectrum effects • low rate of side-effects • The starting dose of levetiracetam is typically 500 mg BID, • The dose can be titrated by 500-1000 mg every 1-2 weeks until maximum benefit • children aged 6-12 years used mean doses of 40mg/kg/day
  • 22. FORMS • TABLETS OF 250 mg, 500 mg, 1000mg, • Solution form • Parenteral form(phase iv trails )